BioHarvest Sciences (BHST) Registration Filing summary

Company overview and business model

• Operates as a biotechnology company utilizing a proprietary Botanical Synthesis Platform Technology to produce active plant ingredients at industrial scale without growing the whole plant, focusing on nutraceuticals, cosmeceuticals, and CDMO services for health and wellness markets.

• Main product is VINIA®, a red grape cell powder marketed as a dietary supplement, with expansion plans into cosmeceuticals and new nutraceuticals such as an Olive Cell compound targeting liver health.

• CDMO business unit offers development and manufacturing of plant-based molecules for pharmaceutical, nutraceutical, and cosmeceutical clients.

Financial performance and metrics

• As of June 30, 2025, reported an accumulated deficit of $102,836,000, negative operating cash flow of $2,883,000, and a net loss of $6,418,000 for the six months ended June 30, 2025.

• For the year ended December 31, 2024, reported an accumulated deficit of $96,418,000, negative operating cash flow of $6,684,000, and a net loss of $12,913,000.

• Total assets as of June 30, 2025, were $27,798,000, with current assets of $10,326,000 and current liabilities of $17,105,000.

Use of proceeds and capital allocation

• Proceeds from the offering are intended for research and development, manufacturing, marketing, advancing the CDMO business, debt reduction or refinancing, capital expenditures, and general corporate purposes including working capital.

• Management retains broad discretion over allocation of funds and may re-allocate based on business needs or results.